Mutation in this complex in lymphoma has been described, showing that about 39% of DLBCL and 41% of follicular lymphoma patients have genomic deletions and/or somatic mutations that inactivate or remove the acetyltransferase domain of EP300 and CREBBP [19]. This evidence concerns the gene EP300 and lymphoma.